Rodrigo Morales, MD
Pulmonary Disease · Warner Robins, GANPI 1780609867
Payments from drug & device makers
Across 528 payments — averaging $48.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$11K
- Olympus Corporation Of The Americas$3K
- Harmony Biosciences LLC$2K
- Jazz Pharmaceuticals Inc.$1K
- Insmed, Inc.$957
- GSK$925
- plus $7K from 40 others
What the payments were for
- Consulting fees$6803%
- Speaking & faculty fees$8,42033%
- Travel & lodging$4,12916%
- Food & beverage$10,72542%
- Education$1,4566%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$10,671
- SINGLE USE SUCTION VALVE (Sterile)$844
- Spiration Valve System$630
- TEZSPIRE$249
- Prolastin-C Liquid$104
How this compares
$25,410 in reported general payments places this provider in the 80th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 691 | $612,828 |
| OfevNintedanib Esylate | 42 | $601,573 |
| XywavSodium,calcium,mag,pot Oxybate | 24 | $367,279 |
| WakixPitolisant Hcl | 13 | $187,646 |
| OpsumitMacitentan | 12 | $151,624 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $148,811 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 128 | $101,427 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 135 | $78,975 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 116 | $61,303 |
| Spiriva RespimatTiotropium Bromide | 69 | $60,701 |
| EliquisApixaban | 54 | $57,017 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $47,393 |
| Advair HfaFluticasone Propion/Salmeterol | 57 | $29,050 |
| JardianceEmpagliflozin | 21 | $26,553 |
| XareltoRivaroxaban | 37 | $23,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Jardiance, Combivent Respimat | $582 | $778,138283 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $925 | $736,551922 claims |
| Harmony Biosciences LLCWakix | $1,644 | $187,64613 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $526 | $151,62412 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $104 | $148,81113 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $795 | $123,028198 claims |
| PfizerEliquis | $50 | $57,01754 claims |
| MerckJanuvia, Dulera | $75 | $31,71142 claims |
| Johnson & JohnsonXarelto | $73 | $23,47537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Warner Robins
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.